RT Journal Article
SR Electronic
T1 Epidemiological and clinical insights from SARS-CoV-2 RT-PCR cycle amplification values
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.15.21253653
DO 10.1101/2021.03.15.21253653
A1 Alizon, Samuel
A1 Selinger, Christian
A1 Sofonea, Mircea T.
A1 Haim-Boukobza, Stéphanie
A1 Giannoli, Jean-Marc
A1 Ninove, Laetitia
A1 Pillet, Sylvie
A1 Vincent, Thibault
A1 de Rougemont, Alexis
A1 Tumiotto, Camille
A1 Solis, Morgane
A1 Stephan, Robin
A1 Bressollette-Bodin, Céline
A1 Salmona, Maud
A1 L’Honneur, Anne-Sophie
A1 Behillil, Sylvie
A1 Lefeuvre, Caroline
A1 Dina, Julia
A1 Hantz, Sébastien
A1 Hartard, Cédric
A1 Veyer, David
A1 Delagrèverie, Héloïse M
A1 Fourati, Slim
A1 Visseaux, Benoît
A1 Henquell, Cécile
A1 Lina, Bruno
A1 Foulongne, Vincent
A1 Burrel, Sonia
A1 SFM COVID-19 study group
YR 2021
UL http://medrxiv.org/content/early/2021/03/17/2021.03.15.21253653.abstract
AB The SARS-CoV-2 pandemic has led to an unprecedented daily use of molecular RT-PCR tests. These tests are interpreted qualitatively for diagnosis, and the relevance of the test result intensity, i.e. the number of amplification cycles (Ct), is debated because of strong potential biases. We analyze a national database of tests performed on more than 2 million individuals between January and November 2020. Although we find Ct values to vary depending on the testing laboratory or the assay used, we detect strong significant trends with patient age, number of days after symptoms onset, or the state of the epidemic (the temporal reproduction number) at the time of the test. These results suggest that Ct values can be used to improve short-term predictions for epidemic surveillance.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04738331Funding StatementThis study did not receive any specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Internal Review Board of the University Hospital of Montpellier (France).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon publication of the manuscript.